This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

For years, the CRISPR-Cas9 genome technology has been reshaping genetic engineering, a precision tool to transform everything from agriculture to medicine. With its incredible efficiency ...

Interference No. 106,115 was the second interference between UC and Broad over patent rights to CRISPR-Cas9 technology in eukaryotic cells. The first interference concluded in 2018 after an appeal ...

CRISPR-Cas9 is a powerful gene editing system that has revolutionized our ability to treat disease and probe the human genome. CRISPR has been used to edit the genomes of animals, plants, and microbes ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Here the authors present an approach called scCLEAN, which uses CRISPR/Cas9 to target and remove certain ubiquitous transcripts, thereby enhancing the detection of low-abundance transcripts.

With this extension, the company’s Malaysian subsidiary, Biocon Sdn Bhd, will continue to supply recombinant human insulin products till October 2025. The extension is part of an existing three ...

The company manufactures a range of recombinant human insulin products at its state- of- the- art facility in Johor, Malaysia. These insulin products are distributed in Malaysia through its commercial ...

The organisation noted that the average net cost of these insulin products is 20% lower than in 2007. In a statement, PhRMA president and CEO, Stephen Ubl, said, “Too often these savings are not ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

As a pioneer in diabetes care, Novo Nordisk has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 ...